News & Events
22 Dec 2011 Invitation to apply to become an independent assessor of group 2 driving licence applicants
People with diabetes treated with insulin are now able to apply for any group two driving licence . The process of assessment will be
1) A driver wishing to apply for a Group 2 licence will first have to fill out a self-declaration form and consent.
2)Information will be obtained from their clinician (Consultant or GP). This will generate a fee that will be paid by the DVLA. Applicants who clearly fail on the criteria will not proceed further. Applicants whose application is rejected can reapply in the future if their circumstances change.
3) The DVLA will refer applicants who meet the criteria for an independent assessment by a consultant diabetologist, who will report to DVLA. A fee will be paid by the DVLA.
4) The final decision as to fitness to drive a class 2 vehicle will lie with the DVLA.
5) There is a right of appeal to a local magistrates or sheriffs court.
Although local diabetologists known to the patient may be involved at stage 2, the DVLA requires a rigorous independent assessment at stage 3. ABCD has agreed to assist the DVLA in identifying assessors for stage 3 (the independent assessment).Discussions are proceeding to set up a training programme for any consultant diabetologist holding a CST wishing to be an independent assessor. Meanwhile in view of the need to establish the assessment process without delay, consultants holding a CST in diabetes who feel that they have appropriate experience are invited to apply to the DVLA using the attached form.
Click here to download the application form.
In this study 34% of the participants had diabetes, Results: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure (NEJM)
Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS
No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study (Takeda)
Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care
The RAMP-DM resulted in greater improvements in HbA1c and reduction in observed and predicted cardiovascular risks at 12 months follow-up, which indicated a risk-stratification multidisciplinary intervention was an effective strategy for managing Chinese people with diabetes in the primary care setting (Cardiovascular Diabetology)
Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study
There are patients for whom glycaemic control worsens and a majority remained above the recommended level, suggesting an unmet need despite the availability of many OAD (BMC Endocrine Disorders)
Postpartum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus
This is the first report that identifies C-peptide and ghrelin as potential biomarkers for the prediction of type 2 diabetes in women with a history of GDM (Journal of Diabetes)